Current Treatment of Myasthenia Gravis

Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with a high mortality rate in the early 20th centu...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhaidar, Mohammed K., Abumurad, Sumayyah, Soliven, Betty, Rezania, Kourosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950430/
https://www.ncbi.nlm.nih.gov/pubmed/35329925
http://dx.doi.org/10.3390/jcm11061597
_version_ 1784675139494871040
author Alhaidar, Mohammed K.
Abumurad, Sumayyah
Soliven, Betty
Rezania, Kourosh
author_facet Alhaidar, Mohammed K.
Abumurad, Sumayyah
Soliven, Betty
Rezania, Kourosh
author_sort Alhaidar, Mohammed K.
collection PubMed
description Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with a high mortality rate in the early 20th century to a treatable condition with a large proportion of patients attaining very good disease control. This review summarizes the current treatment options for MG, including non-immunosuppressive and immunosuppressive treatments, as well as thymectomy and targeted immunomodulatory drugs.
format Online
Article
Text
id pubmed-8950430
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89504302022-03-26 Current Treatment of Myasthenia Gravis Alhaidar, Mohammed K. Abumurad, Sumayyah Soliven, Betty Rezania, Kourosh J Clin Med Review Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with a high mortality rate in the early 20th century to a treatable condition with a large proportion of patients attaining very good disease control. This review summarizes the current treatment options for MG, including non-immunosuppressive and immunosuppressive treatments, as well as thymectomy and targeted immunomodulatory drugs. MDPI 2022-03-14 /pmc/articles/PMC8950430/ /pubmed/35329925 http://dx.doi.org/10.3390/jcm11061597 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alhaidar, Mohammed K.
Abumurad, Sumayyah
Soliven, Betty
Rezania, Kourosh
Current Treatment of Myasthenia Gravis
title Current Treatment of Myasthenia Gravis
title_full Current Treatment of Myasthenia Gravis
title_fullStr Current Treatment of Myasthenia Gravis
title_full_unstemmed Current Treatment of Myasthenia Gravis
title_short Current Treatment of Myasthenia Gravis
title_sort current treatment of myasthenia gravis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950430/
https://www.ncbi.nlm.nih.gov/pubmed/35329925
http://dx.doi.org/10.3390/jcm11061597
work_keys_str_mv AT alhaidarmohammedk currenttreatmentofmyastheniagravis
AT abumuradsumayyah currenttreatmentofmyastheniagravis
AT solivenbetty currenttreatmentofmyastheniagravis
AT rezaniakourosh currenttreatmentofmyastheniagravis

Ejemplares similares